Similarly, a randomized phase III trial of chemotherapy with or without lestaurtinib in patients with FLT3-mutated AML in first relapse demonstrated no difference in the primary endpoint of CR rates (26 vs 21%, p = 0.35) (42). This evidence concerns the gene FLT3 and acute myeloid leukemia.